发明授权
US08759341B2 Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof
有权
双环和三环吲唑取代的1,4-二氢吡啶衍生物及其用途
- 专利标题： Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof
- 专利标题（中）： 双环和三环吲唑取代的1,4-二氢吡啶衍生物及其用途
-
申请号： US13201482申请日： 2010-02-05
-
公开(公告)号： US08759341B2公开(公告)日： 2014-06-24
- 发明人: Martin Michels , Markus Follmann , Alexandros Vakalopoulos , Katja Zimmermann , Mario Lobell , Nicole Teusch , Shendong Yuan
- 申请人： Martin Michels , Markus Follmann , Alexandros Vakalopoulos , Katja Zimmermann , Mario Lobell , Nicole Teusch , Shendong Yuan
- 申请人地址： DE Monheim
- 专利权人： Bayer Intellectual Property GmbH
- 当前专利权人： Bayer Intellectual Property GmbH
- 当前专利权人地址： DE Monheim
- 国际申请： PCT/EP2010/000718 WO 20100205
- 国际公布： WO2010/094405 WO 20100826
- 主分类号： C07D401/04
- IPC分类号： C07D401/04 ; C07D471/04 ; C07D491/048 ; C07D491/147 ; C07D491/153 ; C07D495/04 ; C07D498/14
摘要：
This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.